for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

IVERIC bio Inc

ISEE.OQ

Latest Trade

7.00USD

Change

0.26(+3.86%)

Volume

177,528

Today's Range

6.86

 - 

7.10

52 Week Range

0.91

 - 

8.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.74
Open
7.06
Volume
177,528
3M AVG Volume
45.55
Today's High
7.10
Today's Low
6.86
52 Week High
8.97
52 Week Low
0.91
Shares Out (MIL)
47.88
Market Cap (MIL)
335.18
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Iveric Bio Files For Offering Of Up To 6.25 Million Shares Of Common Stock

Iveric Bio Inc Announces Pricing Of Public Offering Of Common Stock

Iveric Bio Announces Proposed Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About IVERIC bio Inc

IVERIC bio, Inc., formerly Ophthotech Corporation, is a biopharmaceutical company. The Company is focused on the discovering and developing of novel gene therapy solutions to treat orphan inherited retinal diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. The Company’s BEST1 gene encodes a multifunctional protein known as bestrophin1, that regulates ion transport and intracellular calcium signaling in retina cells and helps maintain homeostasis in the sub retinal space between photoreceptors and the retinal pigment epithelial (RPE) cells. Its IC-200 is a mutation independent gene therapy, delivered by an AAV2 vector.

Contact Info

1 Penn Plz Fl 35

+1.212.8458200

https://ivericbio.com/

Executive Leadership

David R. Guyer

Executive Chairman of the Board

Glenn P. Sblendorio

President, Chief Executive Officer, Director

David Francis Carroll

Chief Financial Officer, Senior Vice President, Treasurer

Keith Westby

Chief Operating Officer, Senior Vice President

Abraham Scaria

Chief Scientific Officer

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-5.450

2017

3.170

2018

-1.670

2019(E)

-1.270
Price To Earnings (TTM)
4.33
Price To Sales (TTM)
--
Price To Book (MRQ)
3.26
Price To Cash Flow (TTM)
5.33
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
57.06
Return on Equity (TTM)
52.33

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up